Brand & Marketing

UniQure sells hemophilia gene therapy royalty rights

UniQure made an announcement that it has sold a portion of the royalties worth $400 million it expects to get from the...

Latest news

Merck’s Evobrutinib Encounters Setbacks in MS Trials Amid BTK Inhibitor Challenges

Merck KGaA's foray into the competitive BTK inhibitor space has hit a roadblock, with its highly-touted contender,...

Lilly’s Jaypirca leads the leukemia trail with FDA approval

In the highly competitive landscape of BTK inhibitors for blood cancer treatment, Eli Lilly has set itself...

Merus Faces Setback Following Interim Report for Lung Cancer Therapy

Merus, a biopharmaceutical company, confronted a significant setback following an interim report on the progress of MCLA-129,...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Rett syndrome drug by Acadia approved by U.S. FDA

The U.S. Food and Drug Administration (FDA)...

Roche’s Xofluza approved by European Commission for children’s influenza treatment

The EC (European Commission) has approved Roche’s...